Publication:
VI-RADS-based algorithm for bladder cancer management: randomized retrospective study

dc.contributor.coauthorOzdemir, Merve Sam
dc.contributor.coauthorKeskin, Emin Taha
dc.contributor.coauthorSavun, Metin
dc.contributor.coauthoraya, Nurullah
dc.contributor.coauthorOzdemir, Harun
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.kuauthorYüzkan, Sabahattin
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.date.accessioned2025-03-06T21:01:29Z
dc.date.issued2024
dc.description.abstractOBJECTIVE To evaluate if VI-RADS can distinguish between nonmuscle-invasive bladder cancers (NMIBC), muscle-invasive bladder cancer (MIBC), and high-risk nonmuscle-invasive bladder cancers (HR-NMIBCs). It is unclear if the Vesical Imaging-Reporting and Data System (VIRADS) can replace repeated transurethral resection of bladder tumor (Re-TURBT) as in the new VI-RADS-based algorithm. METHODS Sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values of the VIRADS score were calculated for mpMRI performance in patients undergoing TURBT and HRNMIBC patients for only Re-TURBT. RESULTS Of 283 cases, when VI-RADS >= 3 lesions were considered muscle-invasive, its sensitivity was 95.7% and specificity was 92.5%. PPV and NPV were 86.6% and 97.7%, respectively. The area under the curve (AUC) was 0.942 (P < .001). Of 89 patients undergoing post-Re-TURBT, 41 (46%) were tumor-free, 47 (50.5%) showed permanent HR-NMIBC, and 3 (2.2%) were upgraded to MIBC. Per the new VI-RADS-based approach, 73 (41%) of the 178 HR-NMIBCs with VI-RADS <= 2 would not undergo Re-TURBT. Of the 75 patients with VI-RADS >= 4, 6 (6) with HR-NMIBCs (8%) would not undergo Re-TURBT. When incomplete resections were excluded, 35 (60.3%) of the patients had complete resection, 23 (39.7%) had residual disease, and complete resection would not have been performed in these patients, and 2 (100%) still had residual disease. CONCLUSION The new VI-RADS-based algorithm helped VI-RADS >= 4 patients by switching to radical treatment. Since the residual disease is high in cases with VI-RADS <= 2, even if incomplete resections are excluded, TURBT should be continued. UROLOGY 194: 225-230, 2024. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.identifier.doi10.1016/j.urology.2024.10.002
dc.identifier.eissn1527-9995
dc.identifier.issn0090-4295
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-85207805199
dc.identifier.urihttps://doi.org/10.1016/j.urology.2024.10.002
dc.identifier.urihttps://hdl.handle.net/20.500.14288/27992
dc.identifier.volume194
dc.identifier.wos1376781700001
dc.keywordsVI-RADS
dc.keywordsBladder cancer
dc.keywordsAlgorithm
dc.keywordsManagement
dc.keywordsRandomized retrospective study
dc.keywordsMultiparametric MRI
dc.keywordsRisk stratification
dc.language.isoeng
dc.publisherElsevier Inc.
dc.relation.ispartofUrology
dc.subjectUrology and nephrology
dc.titleVI-RADS-based algorithm for bladder cancer management: randomized retrospective study
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorYüzkan, Sabahattin
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2KUH (Koç University Hospital)
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files